Alnylam

News

Sanofi and Alnylam conclude research phase of RNAi alliance

Sanofi and Alnylam have agreed to conclude the research and option phase of their 2014 RNAi therapeutics alliance for developing drugs for rare genetic diseases.

News

FDA approves Ionis/Akcea's Tegsedi RNAi drug, taking on Alny...

The FDA has approved Ionis Pharmaceuticals’ RNA silencing drug Tegsedi (inotersen) for nerve damage caused by a rare disease.

News

Alnylam rare disease drug may be delayed

Alnylam may have to put hold off plans for an early FDA approval for its gene-silencing drug givosiran – because recruitment to a rare disease trial is going better than expected.<

News

Alnylam's Onpattro is first ever FDA-approved RNAi drug

Onpattro will cost $450,000 a year

Market Access

Vertex and Alnylam orphan drugs set for EU approval

Orphan drugs for cystic fibrosis and the hereditary rare disease hATTR are on course for European approval after winning the backing of a key regulatory advisory committee.

News

Nektar, BioMarin, and Alnylam top list of biotech M&A target...

With Takeda’s £46 billion acquisition of Shire, it’s been a busy year for pharma M&A – and according to analysts Datamonitor, the specialist biotechs Nektar, BioMarin and Alnylam are th

Sanofi and Alnylam conclude research phase of RNAi alliance

FDA approves Ionis/Akcea's Tegsedi RNAi drug, taking on Alny...

Alnylam rare disease drug may be delayed

Alnylam's Onpattro is first ever FDA-approved RNAi drug

Vertex and Alnylam orphan drugs set for EU approval

Nektar, BioMarin, and Alnylam top list of biotech M&A target...

CHMP decision levels the playing field for GSK's RSV jab

How to meet your physicians where they are online

Alnylam

Editor's Picks